These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 20874253

  • 1. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis.
    Bendtzen K.
    J Interferon Cytokine Res; 2010 Oct; 30(10):759-66. PubMed ID: 20874253
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
    Bartosik-Psujek H, Stelmasiak Z.
    Neurol Neurochir Pol; 2004 Oct; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
    [Abstract] [Full Text] [Related]

  • 4. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
    Jensen PE, Sellebjerg F, Søndergaard HB, Sørensen PS.
    Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
    [Abstract] [Full Text] [Related]

  • 5. [The methods of detection of binding and neutralizing antibodies to preparations of interferon-beta].
    Nazarov VD, Lapin SV, Surkova EA, Makshakov GS, Mazing AV, Evdoshenko EP, Totolian AA.
    Klin Lab Diagn; 2016 Oct; 61(10):710-4. PubMed ID: 30615336
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A novel assay to detect low-titred antibodies to interferon beta in multiple sclerosis patients.
    Di Marco P, Pagnotti P, Bellomi F, De Vito G, Sessa E, Bagnato F, Scagnolari C, Bramanti P, Antonelli G.
    New Microbiol; 2006 Jan; 29(1):11-8. PubMed ID: 16608120
    [Abstract] [Full Text] [Related]

  • 10. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
    Seres E, Vécsei L.
    Ideggyogy Sz; 2006 May 20; 59(5-6):156-62. PubMed ID: 16786710
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis.
    Bertolotto A.
    Curr Opin Neurol; 2004 Jun 20; 17(3):241-6. PubMed ID: 15167056
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity of an interferon-beta1a product.
    Kauffman MA, Sterin-Prync A, Papouchado M, González E, Vidal AJ, Grossberg SE, Chuppa S, Odoriz B, Vrech C, Diez RA, Ferro HH.
    Int J Immunopathol Pharmacol; 2011 Jun 20; 24(2):499-504. PubMed ID: 21658324
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Commentary on neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Whitaker JN.
    Arch Neurol; 2001 Aug 20; 58(8):1301. PubMed ID: 11493175
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Can we get rid of neutralizing antibodies against interferon-β?
    Buttmann M, Toyka KV.
    Eur J Neurol; 2009 Jan 20; 16(1):7-9. PubMed ID: 19087143
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
    Kivisäkk P, Alm GV, Tian WZ, Matusevicius D, Fredrikson S, Link H.
    Mult Scler; 1997 Jun 20; 3(3):184-90. PubMed ID: 9310964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.